Format

Send to

Choose Destination
Expert Opin Investig Drugs. 2016 Oct;25(10):1231-7. doi: 10.1080/13543784.2016.1221924. Epub 2016 Aug 22.

Ibudilast for the treatment of multiple sclerosis.

Author information

1
a Department of Neurology , University of Rochester Medical Center , Rochester , NY , USA.

Abstract

INTRODUCTION:

Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS) characterized by inflammatory demyelination and progressive axonal loss. Clinically, this is manifest as relapsing and remitting neurological symptoms and progressive accumulation of disability. Ibudilast is a nonselective phosphodiesterase inhibitor which works by blocking the cleavage of cyclic adenosine monophosphate (cAMP). It has been found to have anti-inflammatory and neuroprotective properties in animal studies and in-vitro studies; it is currently being studied in progressive MS.

AREAS COVERED:

This article reviews various studies looking at ibudilast as a potential therapy for MS. It summarizes prior and current clinical trials of ibudilast in MS as well as its pharmacology.

EXPERT OPINION:

Although ibudilast has not been found to decrease the focal inflammatory activity in relapsing MS, it was shown to have an effect on preserving brain volume and disability progression. Ibudilast may have a role in the treatment of progressive MS phenotypes.

KEYWORDS:

Multiple sclerosis; cerebral atrophy; experimental therapy; neurodegeneration

PMID:
27501293
DOI:
10.1080/13543784.2016.1221924
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center